Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neelima Denduluri

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
JAMA Oncology|June 2, 2022
Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical TrialMiguel Martin, Roberto Hegg, Sung-Bae Kim, et al.
The Lancet. Oncology|October 5, 2023
Measuring ovarian toxicity in clinical trials: an American Society of Clinical Oncology research statementWanda Cui, Rodney P Rocconi, Ramya Thota, et al.
The New England Journal of Medicine|December 12, 2019
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast CancerShanu Modi, Cristina Saura, Toshinari Yamashita, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 12, 2024
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01Aditya Bardia, Komal Jhaveri, Seock-Ah Im, et al.
Journal of Pain and Symptom Management|November 26, 2018
Pretreatment Psychoneurological Symptoms and Their Association With Longitudinal Cognitive Function and Quality of Life in Older Breast Cancer SurvivorsDanielle B Tometich, Brent J Small, Judith E Carroll, et al.
Cancer|September 26, 2019
Sleep disturbance and neurocognitive outcomes in older patients with breast cancer: Interaction with genotypeJudith E Carroll, Brent J Small, Danielle B Tometich, et al.
Cancer|December 21, 2019
Symptom burden among older breast cancer survivors: The Thinking and Living With Cancer (TLC) studyJeanne S Mandelblatt, Wanting Zhai, Jaeil Ahn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2018
Cancer-Related Cognitive Outcomes Among Older Breast Cancer Survivors in the Thinking and Living With Cancer StudyJeanne S Mandelblatt, Brent J Small, Gheorghe Luta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2021
Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0Sara M Tolaney, Elizabeth Garrett-Mayer, Julia White, et al.
Breast Cancer Research : BCR|March 15, 2019
PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trialStephen K L Chia, Miguel Martin, Frankie A Holmes, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
JAMA Oncology|June 2, 2022
Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical TrialMiguel Martin, Roberto Hegg, Sung-Bae Kim, et al.
The Lancet. Oncology|October 5, 2023
Measuring ovarian toxicity in clinical trials: an American Society of Clinical Oncology research statementWanda Cui, Rodney P Rocconi, Ramya Thota, et al.
The New England Journal of Medicine|December 12, 2019
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast CancerShanu Modi, Cristina Saura, Toshinari Yamashita, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 12, 2024
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01Aditya Bardia, Komal Jhaveri, Seock-Ah Im, et al.
Journal of Pain and Symptom Management|November 26, 2018
Pretreatment Psychoneurological Symptoms and Their Association With Longitudinal Cognitive Function and Quality of Life in Older Breast Cancer SurvivorsDanielle B Tometich, Brent J Small, Judith E Carroll, et al.
Cancer|September 26, 2019
Sleep disturbance and neurocognitive outcomes in older patients with breast cancer: Interaction with genotypeJudith E Carroll, Brent J Small, Danielle B Tometich, et al.
Cancer|December 21, 2019
Symptom burden among older breast cancer survivors: The Thinking and Living With Cancer (TLC) studyJeanne S Mandelblatt, Wanting Zhai, Jaeil Ahn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2018
Cancer-Related Cognitive Outcomes Among Older Breast Cancer Survivors in the Thinking and Living With Cancer StudyJeanne S Mandelblatt, Brent J Small, Gheorghe Luta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2021
Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0Sara M Tolaney, Elizabeth Garrett-Mayer, Julia White, et al.
Breast Cancer Research : BCR|March 15, 2019
PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trialStephen K L Chia, Miguel Martin, Frankie A Holmes, et al.
Pageof 6